The role of mitochondrial dicarboxylate carrier SLC25A10 in succinate-dependent mitochondrial permeability transition induced by fasiglifam　　　　　　　　　　　　　　　
The 40th Annual Meeting of the Japanese Society for the Study of Xenobiotics (JSSX), Oct. 2025

Mitochondrial proteomic alterations in the metabolic dysfunction-associated steatotic liver disease　　　　　　　　　　　　　　　
Aug. 2025

Fasiglifam-Induced mitochondrial swelling and its underlying mechanism　　　　　　　　　　　　　　　
Jul. 2025

Investigation of hepatotoxicant-induced mitochondrial swelling and its regulatory factors　　　　　　　　　　　　　　　
May 2025

Analysis of lipid metabolic pathways involved in mitochondrial permeability transition　　　　　　　　　　　　　　　
Mar. 2025

Omics-based exploration of molecular mechanisms in hepatotoxicant-induced mitochondrial dysfunction　　　　　　　　　　　　　　　
Mar. 2025

Integrated omics profiling in metabolic dysfunction-associated steatotic liver disease　　　　　　　　　　　　　　　
Dec. 2024

Identification of mitochondrial alterations and their regulatory factors in steatotic liver disease through comparative omics analysis　　　　　　　　　　　　　　　
1st Asia & Pacific Bioinformatics Joint Conference, Oct. 2024

Omics data-based analysis of mitochondrial characteristics and toxicity mechanisms　　　　　　　　　　　　　　　
26th North American ISSX and 39th JSSX Meeting (Honolulu, Hawaii), Sep. 2024

Analysis of mitochondrial susceptibility to hepatotoxicants in aged steatotic liver　　　　　　　　　　　　　　　
Jul. 2024

Mitochondrial proteomic alterations in the metabolic dysfunction-associated steatotic liver disease　　　　　　　　　　　　　　　
Jun. 2024

脂肪性肝疾患のミトコンドリア機能変化に対するプロテオミクス研究　　　　　　　　　　　　　　　
May 2024

ミトコンドリア毒性感受性を制御するトランスポーターの探索　　　　　　　　　　　　　　　
May 2024

Omics data-based analysis of non-alcoholic fatty liver disease pathogenesis　　　　　　　　　　　　　　　
Mar. 2024

Alterations in transporter expression in hepatic mitochondria of obese NAFLD　　　　　　　　　　　　　　　
Dec. 2023

Identification of upstream factors that regulate susceptibility to drug-induced mitochondrial toxicity in NAFLD　　　　　　　　　　　　　　　
Oct. 2023

Mechanisms of adaptation of liver mitochondrial respiratory function in nonalcoholic fatty liver disease　　　　　　　　　　　　　　　
Oct. 2023

Proteomic approach to identify the mechanisms of increased susceptibility to a hepatotoxic drug-induced mitochondrial permeability transition　　　　　　　　　　　　　　　
Sep. 2023

Proteomic analysis of mitochondria to elucidate the immune-mediated drug-induced liver injury in NAFLD　　　　　　　　　　　　　　　
Sep. 2023

Proteomic analysis of NAFLD mitochondria to elucidate MPT-dependent immune responses　　　　　　　　　　　　　　　
Jul. 2023

Interaction between mitochondrial toxicity and bile acid toxicity as a mechanism of drug-induced liver injury　　　　　　　　　　　　　　　
Jun. 2023

Differences in liver mitochondrial susceptibility to drug stress between NAFLD mouse models　　　　　　　　　　　　　　　
Mar. 2023

Comprehensive analysis of NAFLD mitochondrial responsiveness for the development of a novel risk assessment system for drug-induced liver injury　　　　　　　　　　　　　　　
Nov. 2022

Proteomic analysis of NAFLD mice liver mitochondria following exposure to hepatotoxic drug　　　　　　　　　　　　　　　
Jun. 2022

Mitochondrial permeability transition as a mechanism of drug-induced liver injury in NAFLD　　　　　　　　　　　　　　　
Mar. 2022

Mitochondrial dysfunction is a possible determinant of susceptibility to drug-induced hepatotoxicity in NAFLD　　　　　　　　　　　　　　　
Nov. 2021

Mitochondrial permeability transition as a trigger of immune-mediated drug-induced liver injury in obese type 2 diabetes　　　　　　　　　　　　　　　
Sep. 2021

Mitochondrial permeability transition and drug-induced liver injury in a type 2 diabetic mouse model　　　　　　　　　　　　　　　
Mar. 2021

Increased gut permeability and tight junction alterations in methotrexate-treated rats　　　　　　　　　　　　　　　
2010

Protective effect and mechanisms of rebamipide on the methotrexate-induced intestinal epithelial barrier dysfunction in rats　　　　　　　　　　　　　　　
2009

メトトレキサート投与ラット小腸粘膜透過性に対するレバミピドの防御効果　　　　　　　　　　　　　　　
2007, [Invited]

メトトレキサート誘発性消化管障害に対する抗潰瘍薬の防御効果の検討　　　　　　　　　　　　　　　
2007, [Invited]

マルチオミクスに基づく脂肪肝のミトコンドリア介在薬物肝毒性機構の免疫学的統合解析
01 Apr. 2025 - 31 Mar. 2028

Mitochondrial permeability transition as a mechanism of immune-mediated drug-induced liver injury in NAFLD
Grant-in-Aid for Scientific Research (C)
Teikyo Heisei University
Apr. 2022 - Mar. 2025

Regulatory T cells and drug-induced liver injury in type 2 diabetes
Grant-in-Aid for Scientific Research (C)
Teikyo Heisei University
Apr. 2019 - Mar. 2024

C型肝炎時の肝細胞内ヘム代謝に着目した薬剤性肝障害メカニズムの解明
Apr. 2016 - Mar. 2018

Analysis of idiosyncratic drug toxicity using mitochondria isolated from an animal model of metabolic syndrome
Grant-in-Aid for Challenging Exploratory Research
Teikyo Heisei University
Apr. 2014 - Mar. 2016
Although it has been suggested that underlying disease could be a nongenetic risk factor for idiosyncratic drug-induced liver injury (DILI), little is known about the mechanisms that determine the increased sensitivity to DILI. In addition to patient risk factors, drug related risk factors including mitochondrial toxicity have also been proposed to explain the complex mechanisms of DILI. The objective of this study was to determine whether the fatty liver in type 2 diabetes (T2D) is more susceptible to mitochondrial permeability transition (MPT), characterized by swelling and membrane depolarization that are associated with DILI. Our result showed that T2D enhanced susceptibility to drug-induced MPT. We also demonstrated that the liver mitochondria isolated from T2D mice had increased oxygen consumption stimulated by an uncoupler compared to normal liver mitochondria (NLM). It might be a useful tool to predict DILI in T2D patients, because its sensitivity to drug is different from NLM.

メトトレキサートによる小腸上皮バリア機能障害の機序解明を目指した研究　　　　　　　　　　　　　　　
Apr. 2009 - Mar. 2010